Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: Findings from the REACH registry

Clinical Cardiology

Volumn 36, Issue 12, 2013, Pages 721-727

  Rodriguez, Fátima ^a,b   Cannon, Christopher P ^a,b   Steg, Ph Gabriel ^c   Kumbhani, Dharam J ^d   Goto, Shinya ^e   Smith, Sidney C ^f   Eagle, Kim A ^g   Ohman, E Magnus ^h   Umez Eronini, Amarachi A ^a   Hoffman, Elaine ^a,b   Bhatt, Deepak L ^a,b,i  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^h DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; ASIAN; BODY MASS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY STENT; EVIDENCE BASED PRACTICE; FEMALE; FOLLOW UP; HISPANIC; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; NEWBORN; OUTPATIENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREDICTOR VARIABLE; PROSPECTIVE STUDY; SECONDARY PREVENTION; SELF REPORT; THROMBOSIS; THROMBOSIS PREVENTION; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGE FACTORS; AGED; AMBULATORY CARE; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; CONTINENTAL POPULATION GROUPS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; REGISTRIES; RESIDENCE CHARACTERISTICS; RISK FACTORS; SECONDARY PREVENTION; SELF REPORT; TIME FACTORS; TREATMENT OUTCOME;

EID: 84890121390     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22217     Document Type: Article

References (38)

1. Ho PM, Bryson CL, Rumsfeld JS,. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009; 119: 3028-3035.
2. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006; 113: 203-212.
3. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2006; 47: 2130-2139.
4. Jackevicius CA, Li P, Tu JV,. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation. 2008; 117: 1028-1036.
5. Osterberg L, Blaschke T,. Adherence to medication. N Engl J Med. 2005; 353: 487-497.
6. Kulkarni SP, Alexander KP, Lytle B, et al. Long-term adherence with cardiovascular drug regimens. Am Heart J. 2006; 151: 185-191.
7. Choudhry NK, Setoguchi S, Levin R, et al. Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients. Pharmacoepidemiol Drug Saf. 2008; 17: 1189-1196.
8. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008; 155: 772-779.
9. Wijeysundera HC, Machado M, Farahati F, et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. JAMA. 2010; 303: 1841-1847.
10. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007; 356: 2388-2398.
11. Kumbhani DJ, Steg PG, Cannon CP, et al. Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis. Am J Med. 2013; 126: 693-700.
12. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011; 124: 2458-2473.
13. Kolandaivelu K, Bhatt DL,. Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence. Nat Rev Cardiol. 2010; 7: 461-467.
14. Maddox TM, Ho PM,. Medication adherence and the patient with coronary artery disease: challenges for the practitioner. Curr Opin Cardiol. 2009; 24: 468-472.
15. Kumbhani DJ, Fonarow GC, Cannon CP, et al. Predictors of adherence to performance measures in patients with acute myocardial infarction. Am J Med. 2013; 126:74.e1-74.e9.
16. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006; 295: 180-189.
17. Ohman EM, Bhatt DL, Steg PG, et al. The Reduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J. 2006; 151:786.e1-786.e10.
18. Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010; 304: 1350-1357.
19. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006; 113: 2363-2372.
20. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011; 42: 227-276.
21. Baker DW, Hayes R, Fortier JP,. Interpreter use and satisfaction with interpersonal aspects of care for Spanish-speaking patients. Med Care. 1998; 36: 1461-1470.
22. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006; 166: 1842-1847.
23. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications a cross-national study. JAMA. 1998; 279: 1458-1462.
24. Balkrishnan R., Predictors of medication adherence in the elderly. Clin Ther. 1998; 20: 764-771.
25. Kulik A, Shrank WH, Levin R, et al. Adherence to statin therapy in elderly patients after hospitalization for coronary revascularization. Am J Cardiol. 2011; 107: 1409-1414.
26. Mensah GA, Mokdad AH, Ford ES, et al. State of disparities in cardiovascular health in the united states. Circulation. 2005; 111: 1233-1241.
27. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study) a prospective epidemiological survey. Lancet. 2011; 378: 1231-1243.
28. Roth MT, Esserman DA, Ivey JL, et al. Racial disparities in quality of medication use in older adults: findings from a longitudinal study. Am J Geriatr Pharmacother. 2011; 9: 250-258.
29. Shrank WH,. Helping our patients to adhere to chronic medications a new arrow for the quiver. J Gen Intern Med. 2011; 26: 1394-1395.
30. Bowry AD, Shrank WH, Lee JL, et al. A systematic review of adherence to cardiovascular medications in resource-limited settings. J Gen Intern Med. 2011; 26: 1479-1491.
31. Eagle KA, Kline-Rogers E, Goodman SG, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med. 2004; 117: 73-81.
32. Edmondson D, Horowitz CR, Goldfinger JZ, et al. Concerns about medications mediate the association of posttraumatic stress disorder with adherence to medication in stroke survivors. Br J Health Psychol. 2013; doi:10.1111/bjhp.12022.
33. Kronish IM, Edmondson D, Goldfinger JZ, et al. Posttraumatic stress disorder and adherence to medications in survivors of strokes and transient ischemic attacks. Stroke. 2012; 43: 2192-2197.
34. Qureshi SU, Long ME, Bradshaw MR, et al. Does PTSD impair cognition beyond the effect of trauma? J Neuropsychiatry Clin Neurosci. 2011; 23: 16-28.
35. Lonn E, Bosch J, Teo KK, et al. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation. 2010; 122: 2078-2088.
36. Thom S, Field J, Poulter N, et al. Use of a Multidrug Pill in Reducing Cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe. Eur J Prev Cardiol. 2012; doi:10.1177/2047487312463278.
37. Thom S,. Use of Multidrug Pill in Reducing Cardiovascular Events (UMPIRE): late-breaking clinical trials. American Heart Association Scientific Sessions; November 3-7; Los Angeles, CA: doi:10.1161/CIR.0b013e318278c90d.
38. Gehi AK, Ali S, Na B, et al. Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the Heart and Soul Study. Arch Intern Med. 2007; 167: 1798-1803.